EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Pharmacogenomics in Dentistry: From CYP ‐Mediated Drug Response to Precision Prescribing in Oral Healthcare

Giorgia Pieretto, Jessica Cusato iD, Martina Sansavini iD, Christian Bacci iD

Oral Diseases · 2026-08-21

DOI: 10.1111/odi.70468 ↗

At a glance

Übersichtsarbeit in Oral Diseases, published online on 2026-08-21. Written by Giorgia Pieretto and 3 co-authors. Institution: Department of Neurosciences, University of Padua, Padova, Italy. 81 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

This narrative review critically assesses the clinical relevance of pharmacogenomics within dental genomics, distinguishing clinically actionable applications from emerging or investigational findings. Materials and Methods A targeted literature review was conducted in PubMed/MEDLINE, Scopus and Embase for publications from January 2000 to March 2026. The search focused on gene–drug interactions involving medications commonly prescribed or clinically relevant in dental care, including analgesics, NSAIDs, antiplatelet agents, anticoagulants, antibiotics and local anaesthetics. Relevant guidelines, landmark studies and key reviews were also considered.

Results

Most genomic findings related to oral diseases provide biological insights but limited routine clinical utility. Conversely, selected pharmacogenomic determinants show clearer applicability. CYP2D6 variability is the most robust example, influencing codeine and tramadol efficacy and toxicity. CYP2C9 variants may affect NSAID safety, while CYP2C19, VKORC1 and CYP2C9 are relevant in patients receiving antiplatelet or anticoagulant therapy. Other determinants, including SCN9A, CYP3A4/5 and ABCB1, remain investigational. Drug–drug interactions and phenoconversion further influence real‐world responses.

Conclusion

Pharmacogenomics currently represents the most actionable area of dental genomics. Current evidence supports selective, scenario‐based integration, particularly in pain management, adverse drug reactions, polypharmacy and medically complex patients.

Subjects

Author keywords

analgesicscytochrome P‐450 CYP2D6dentistrydrug interactionsnon‐steroidal anti‐inflammatory agentspharmacogeneticsprecision medicine

Authors and institutions

  • Department of Neurosciences, University of Padua, Padova, Italy.
  • Cancer Institute - IRCCS Candiolo, Candiolo, Italy.
  • Department of Medical Sciences, University of Torino, Torino, Italy.
  • Department of Biomedical and Neuromotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.

ORCID profiles: Jessica Cusato, Martina Sansavini, Christian Bacci

Cite

APA

Pieretto, G., Cusato, J., Sansavini, M., & Bacci, C. (2026). Pharmacogenomics in Dentistry: From CYP ‐Mediated Drug Response to Precision Prescribing in Oral Healthcare. Oral Diseases. https://doi.org/10.1111/odi.70468

Vancouver

Pieretto G, Cusato J, Sansavini M, Bacci C. Pharmacogenomics in Dentistry: From CYP ‐Mediated Drug Response to Precision Prescribing in Oral Healthcare. Oral Diseases. 2026. doi:10.1111/odi.70468

BibTeX
@article{Pieretto2026,
  author = {Pieretto, Giorgia and Cusato, Jessica and Sansavini, Martina and Bacci, Christian},
  title = {Pharmacogenomics in Dentistry: From CYP ‐Mediated Drug Response to Precision Prescribing in Oral Healthcare},
  journal = {Oral Diseases},
  year = {2026},
  doi = {10.1111/odi.70468}
}
Start for free →